Conclusion
While the amount of knowledge on rhinitis and allergic rhinitis in children is continuously increasing, novel approaches mostly deriving from adult populations, have the potential of improving outcomes in children. Considering that blinded randomized trials are more difficult to perform in pediatrics, real-life approaches may be used to confirm the usefulness of these proposals[138]. It is probable that, as in the case of pediatric asthma [139], prevention studies and interventions on the natural history of rhinitis and/or respiratory allergy as a whole, are the highest priority for research and health policy.
REFERENCES
1. Samoliński, B., et al., Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy, 2012. 67 (6): p. 726-31.
2. Georgountzou, A., et al., Age-dependent changes in circulating leukocytes from birth to adulthood in healthy and atopic subjects.Allergy, 2019. 74 (S106): p. 139-139.
3. Fokkens, W.J., et al., European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020.58 (Suppl S29): p. 1-464.
4. Georgountzou, A. and N.G. Papadopoulos, Postnatal Innate Immune Development: From Birth to Adulthood. Front Immunol, 2017. 8 : p. 957.
5. Zhong, H., et al., Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis. Clin Immunol, 2017. 183 : p. 293-299.
6. Hammad, H. and B.N. Lambrecht, Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity, 2015. 43 (1): p. 29-40.
7. Divekar, R. and H. Kita, Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol, 2015. 15 (1): p. 98-103.
8. Wise, S.K., et al., International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol, 2018. 8 (2): p. 108-352.
9. Eifan, A.O. and S.R. Durham, Pathogenesis of rhinitis. Clin Exp Allergy, 2016. 46 (9): p. 1139-51.
10. Peng, Y.Q., et al., Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis. J Allergy Clin Immunol, 2020. 145 (3): p. 855-867 e8.
11. Coomes, S.M., et al., CD4(+) Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol, 2017.10 (1): p. 150-161.
12. Taka, S., et al., MicroRNAs in Asthma and Respiratory Infections: Identifying Common Pathways. Allergy Asthma Immunol Res, 2020. 12 (1): p. 4-23.
13. Zeng, Q., et al., MicroRNA-181a and microRNA-155 are involved in the regulation of the differentiation and function of regulatory T cells in allergic rhinitis children. Pediatr Allergy Immunol, 2019.30 (4): p. 434-442.
14. Yang, Q., et al., Infiltration pattern of gammadelta T cells and its association with local inflammatory response in the nasal mucosa of patients with allergic rhinitis. Int Forum Allergy Rhinol, 2019.9 (11): p. 1318-1326.
15. Eifan, A.O., et al., Reduced T-bet in addition to enhanced STAT6 and GATA3 expressing T cells contribute to human allergen-induced late responses. Clin Exp Allergy, 2012. 42 (6): p. 891-900.
16. Jiao, W.E., et al., Notch Signaling Promotes Development of Allergic Rhinitis by Suppressing Foxp3 Expression and Treg Cell Differentiation. Int Arch Allergy Immunol, 2019. 178 (1): p. 33-44.
17. Yao, Y., et al., CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy, 2020.
18. Wirz, O.F., et al., Comparison of regulatory B cells in asthma and allergic rhinitis. Allergy, 2019. 74 (4): p. 815-818.
19. Arebro, J., et al., A possible role for neutrophils in allergic rhinitis revealed after cellular subclassification. Sci Rep, 2017. 7 : p. 43568.
20. Polak, D., et al., A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions. J Allergy Clin Immunol, 2019. 143 (3): p. 1143-1152 e4.
21. Kota, A., et al., Autophagy and airway fibrosis: Is there a link? F1000Res, 2017. 6 : p. 409.
22. Li, J. and Y. Li, Autophagy is involved in allergic rhinitis by inducing airway remodeling. Int Forum Allergy Rhinol, 2019.9 (11): p. 1346-1351.
23. Papadopoulos, N.G., et al., Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy, 2015. 70 (5): p. 474-94.
24. Papadopoulos, N.G. and G.V. Guibas, Rhinitis Subtypes, Endotypes, and Definitions. Immunol Allergy Clin North Am, 2016.36 (2): p. 215-33.
25. Patel, V.A. and M.M. Carr, Congenital nasal obstruction in infants: A retrospective study and literature review. Int J Pediatr Otorhinolaryngol, 2017. 99 : p. 78-84.
26. Poddighe, D., et al., Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol, 2016. 6 (4): p. 200-213.
27. Lee, K.S., et al., Local Immune Responses in Children and Adults with Allergic and Nonallergic Rhinitis. PLoS One, 2016.11 (6): p. e0156979.
28. Segboer, C.L., et al., Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions. PLoS One, 2018. 13 (7): p. e0200366.
29. Tsilochristou, O., et al., Detection of local allergic rhinitis in children with chronic, difficult-to-treat, non-allergic rhinitis using multiple nasal provocation tests. Pediatr Allergy Immunol, 2019. 30 (3): p. 296-304.
30. Colavita, L., et al., Local Allergic Rhinitis in Pediatric Patients: Is IgE Dosage in Nasal Lavage Fluid a Useful Diagnostic Method in Children? Int J Mol Cell Med, 2017. 6 (3): p. 174-182.
31. Zicari, A.M., et al., Local allergic rhinitis in children: Novel diagnostic features and potential biomarkers. Am J Rhinol Allergy, 2016. 30 (5): p. 329-34.
32. Campo, P., et al., Local allergic rhinitis: Implications for management. Clin Exp Allergy, 2019. 49 (1): p. 6-16.
33. NE, E.L. and M.W. El-Anwar, Assessment of Nasal Immunoglobulin E Level in Atopic and Non-atopic Rhinitis Patients: A Tool for Diagnosis of Local Allergic Rhinitis. Egypt J Immunol, 2016. 23 (1): p. 45-56.
34. Van Gerven, L., B. Steelant, and P.W. Hellings, Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge.Allergy, 2018. 73 (9): p. 1784-1791.
35. Giannico, R., et al., Non-specific nasal provocation in children with chronic allergic rhinitis. J Investig Allergol Clin Immunol, 1996. 6 (2): p. 110-6.
36. Lluch-Bernal, M., et al., Nasal Hyperreactivity: Nonspecific Nasal Provocation Tests. Review by the Rhinoconjunctivitis Committee of the Spanish Society of Allergy and Clinical Immunology. J Investig Allergol Clin Immunol, 2015. 25 (6): p. 396-407.
37. Baroody, F.M., Nonallergic Rhinitis: Mechanism of Action.Immunol Allergy Clin North Am, 2016. 36 (2): p. 279-87.
38. Van Gerven, L., et al., Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. J Allergy Clin Immunol, 2014. 133 (5): p. 1332-9, 1339 e1-3.
39. Steelant, B., et al., Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol, 2016. 137 (4): p. 1043-1053 e5.
40. Hamed, A., et al., Nasal IgE production in allergic rhinitis: Impact of rhinovirus infection. Clin Exp Allergy, 2019. 49 (6): p. 847-852.
41. Doulaptsi, M., et al., Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis. Allergy, 2020.75 (7): p. 1768-1771.
42. Bousquet, J., et al., Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy, 2015.70 (9): p. 1062-78.
43. Anto, J.M., et al., Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol, 2017. 139 (2): p. 388-399.
44. Pinart, M., et al., Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med, 2014. 2 (2): p. 131-40.
45. Bousquet, J., et al., MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.Allergy, 2011. 66 (5): p. 596-604.
46. Blondal, V., et al., Study of atopic multimorbidity in subjects with rhinitis using multiplex allergen component analysis.Clin Transl Allergy, 2020. 10 : p. 6.
47. Gabet, S., et al., Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants. Pediatr Allergy Immunol, 2016. 27 (8): p. 831-837.
48. Ballardini, N., et al., IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence. Allergy, 2016. 71 (3): p. 342-9.
49. Aguilar, D., et al., Computational analysis of multimorbidity between asthma, eczema and rhinitis. PLoS One, 2017. 12 (6): p. e0179125.
50. Aguilar, D., et al., Understanding allergic multimorbidity within the non-eosinophilic interactome. PLoS One, 2019.14 (11): p. e0224448.
51. Ferreira, M.A., et al., Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet, 2017.49 (12): p. 1752-1757.
52. Demenais, F., et al., Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat Genet, 2018. 50 (1): p. 42-53.
53. Lau, S., et al., Allergy and atopy from infancy to adulthood: Messages from the German birth cohort MAS. Ann Allergy Asthma Immunol, 2019. 122 (1): p. 25-32.
54. Toppila-Salmi, S., et al., Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy, 2019. 74 (12): p. 2406-2416.
55. Hohmann, C., et al., Sex-specific incidence of asthma, rhinitis and respiratory multimorbidity before and after puberty onset: individual participant meta-analysis of five birth cohorts collaborating in MeDALL. BMJ Open Respir Res, 2019. 6 (1): p. e000460.
56. Jantunen, J., et al., Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey. Int Arch Allergy Immunol, 2019.179 (4): p. 273-280.
57. Bousquet, J., et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008. 63 Suppl 86 : p. 8-160.
58. Demoly, P., et al., Assessment of disease control in allergic rhinitis. Clin Transl Allergy, 2013. 3 (1): p. 7.
59. Bousquet, J., et al., Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol, 2020.145 (1): p. 70-80 e3.
60. Demoly, P., et al., Validation of a self-questionnaire for assessing the control of allergic rhinitis. Clin Exp Allergy, 2011.41 (6): p. 860-8.
61. Linhares, D.V., et al., Validation of control of allergic rhinitis and asthma test for children (CARATKids)–a prospective multicenter study. Pediatr Allergy Immunol, 2014. 25 (2): p. 173-9.
62. Emons, J.A., et al., Use of the Control of Allergic Rhinitis and Asthma Test (CARATkids) in children and adolescents: Validation in Dutch. Pediatr Allergy Immunol, 2017. 28 (2): p. 185-190.
63. Meltzer, E.O., et al., Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. J Allergy Clin Immunol, 2013. 131 (2): p. 379-86.
64. Morais-Almeida, M., et al., Prevalence and classification of rhinitis in preschool children in Portugal: a nationwide study.Allergy, 2013. 68 (10): p. 1278-88.
65. Bousquet, J., et al., ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy, 2016. 6 : p. 47.
66. Bousquet, J., et al., MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol, 2016. 138 (2): p. 367-374 e2.
67. World Health Organization (WHO). Digital Health . 2018 April 12,2020]; Available from:https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_R7-en.pdf?ua=1.
68. World Health Organization (WHO). Recommendations on digital interventions for health system strengthening . 2019 [cited 2020 April 20]; Available from:https://apps.who.int/iris/bitstream/handle/10665/311941/9789241550505-eng.pdf?ua=1.
69. Gu, T. Newzoo’s Global Mobile Market Report: Insights into the World’s 3.2 Billion Smartphone Users, the Devices They Use & the Mobile Games They Play . 2019; Available from:https://newzoo.com/insights/articles/newzoos-global-mobile-market-report-insights-into-the-worlds-3-2-billion-smartphone-users-the-devices-they-use-the-mobile-games-they-play/.
70. Schaeffer, K. Most U.S. teens who use cellphones do it to pass time, connect with others, learn new things . 2019 [cited 2020 April 21, 2020]; Available from:https://pewresearch-org-preprod.go-vip.co/fact-tank/2019/08/23/most-u-s-teens-who-use-cellphones-do-it-to-pass-time-connect-with-others-learn-new-things/.
71. Bousquet, J., et al., Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol, 2019. 143 (3): p. 864-879.
72. Gray, W.N., et al., Medication adherence in pediatric asthma: A systematic review of the literature. Pediatr Pulmonol, 2018.53 (5): p. 668-684.
73. Pizzulli, A., et al., The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy, 2014. 44 (10): p. 1246-54.
74. Matricardi, P.M., et al., The role of mobile health technologies in allergy care: An EAACI position paper. Allergy, 2020.75 (2): p. 259-272.
75. Bastl, K., U. Berger, and M. Kmenta, Evaluation of Pollen Apps Forecasts: The Need for Quality Control in an eHealth Service. J Med Internet Res, 2017. 19 (5): p. e152.
76. European Council, Regulation 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.Official Journal of the European Union, 2017. 60 : p. 1-175.
77. U.S. Food & Drug Administration (FDA). Policy for Device Software Functions and Mobile Medical Applications . 2019 [cited 2020 April 21]; Available from:https://www.fda.gov/media/80958/download.
78. European Council, Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union, 2016. 59 : p. 1-88.
79. Bousquet, J., et al., Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care? J Allergy Clin Immunol Pract, 2019. 7 (8): p. 2511-2523.
80. Caimmi, D., et al., Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clin Exp Allergy, 2017. 47 (12): p. 1526-1533.
81. Bousquet, J., et al., MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy, 2018. 8 : p. 45.
82. Sleurs, K., et al., Mobile health tools for the management of chronic respiratory diseases. Allergy, 2019. 74 (7): p. 1292-1306.
83. Courbis, A.L., et al., Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy, 2018. 48 (12): p. 1640-1653.
84. L., K., et al., Allergymap: A Hybrid mHealth Mobile Crowdsensing System for Allergic Diseases Epidemiology : a multidisciplinary case study , in 2018 IEEE International Conference on Pervasive Computing and Communications Workshops (Percom Workshops) . 2018, IEEE: Athens. p. 597-602.
85. Roberts, G., et al., Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy, 2013.68 (9): p. 1102-16.
86. Klimek, L., et al., Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int, 2017. 26 (1): p. 16-24.
87. Roche, N., et al., The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. Eur Respir J, 2019. 54 (3).
88. Katotomichelakis, M., et al., Alternaria and Cladosporium calendar of Western Thrace: Relationship with allergic rhinitis symptoms. Laryngoscope, 2016. 126 (2): p. E51-6.
89. Cox, L., Approach to Patients with Allergic Rhinitis: Testing and Treatment. Med Clin North Am, 2020. 104 (1): p. 77-94.
90. Phipatanakul, W., et al., Environmental assessment and exposure reduction of rodents: a practice parameter. Ann Allergy Asthma Immunol, 2012. 109 (6): p. 375-87.
91. Murray, C.S., et al., Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers. Am J Respir Crit Care Med, 2017. 196 (2): p. 150-158.
92. Custovic, A., C.S. Murray, and A. Simpson, Dust-mite inducing asthma: what advice can be given to patients? Expert Rev Respir Med, 2019. 13 (10): p. 929-936.
93. Scadding, G.K., et al., BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy, 2017. 47 (7): p. 856-889.
94. Nurmatov, U.B., et al., Volatile organic compounds and risk of asthma and allergy: a systematic review. Eur Respir Rev, 2015.24 (135): p. 92-101.
95. Burte, E., et al., Association between air pollution and rhinitis incidence in two European cohorts. Environ Int, 2018.115 : p. 257-266.
96. Zhao, F., et al., Common ragweed (Ambrosia artemisiifolia L.): allergenicity and molecular characterization of pollen after plant exposure to elevated NO2. Plant Cell Environ, 2016. 39 (1): p. 147-64.
97. Eguiluz-Gracia, I., et al., The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma.Allergy, 2020.
98. Motola, D., et al., Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf, 2017. 26 (10): p. 1164-1171.
99. Church, M.K., Allergy, Histamine and Antihistamines. Handb Exp Pharmacol, 2017. 241 : p. 321-331.
100. Cataldi, M., et al., Cardiac safety of second-generation H1 -antihistamines when updosed in chronic spontaneous urticaria. Clin Exp Allergy, 2019. 49 (12): p. 1615-1623.
101. Horak, F. and U.P. Zieglmayer, Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol, 2009. 5 (6): p. 659-69.
102. Schumacher, S., et al., Unique immunomodulatory effects of azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch Pharmacol, 2014. 387 (11): p. 1091-9.
103. Karatzanis, A., et al., Contemporary Use of Corticosteroids in Rhinology. Curr Allergy Asthma Rep, 2017. 17 (2): p. 11.
104. Segboer, C., et al., Intranasal corticosteroids for non-allergic rhinitis. Cochrane Database Syst Rev, 2019.2019 (11).
105. Bensch, G.W., Safety of intranasal corticosteroids. Ann Allergy Asthma Immunol, 2016. 117 (6): p. 601-605.
106. Hicks, A. and M. Egan, On-Demand Intranasal Corticosteroids for Treatment of Seasonal Allergic Rhinitis in Children. J Allergy Clin Immunol Pract, 2018. 6 (4): p. 1430-1431.
107. Bousquet, J., et al., Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.Allergy, 2020.
108. Berger, W., et al., Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment. Pediatr Allergy Immunol, 2016. 27 (2): p. 126-33.
109. Debbaneh, P.M., et al., Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg, 2019. 161 (3): p. 412-418.
110. Berger, W., et al., Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc, 2018. 39 (2): p. 110-116.
111. http://cisn.co/2AD11JK.,Dymista approved in children 6 to 11 years of age with seasonal allergic rhinitis . Accessed 12 Oct 2018.
112. Schuler Iv, C.F. and J.M. Montejo, Allergic Rhinitis in Children and Adolescents. Pediatr Clin North Am, 2019. 66 (5): p. 981-993.
113. (FDA), U.S.F.D.A. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis . 2020 [cited 2020 03 Sep]; Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug.
114. Licari, A., et al., Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opin Biol Ther, 2020: p. 1-11.
115. Humbert, M., et al., IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract, 2019. 7 (5): p. 1418-1429.
116. Yu, C., et al., Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Am J Rhinol Allergy, 2020.34 (2): p. 196-208.
117. Kopp, M.V., et al., Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.Clin Exp Allergy, 2009. 39 (2): p. 271-9.
118. Castro, M., et al., Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med, 2018.378 (26): p. 2486-2496.
119. Weinstein, S.F., et al., Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol, 2018. 142 (1): p. 171-177 e1.
120. Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy.  ClinicalTrials.gov identifier:NCT03558997.https://ClinicalTrials.gov/show/NCT03558997.  Updated May 28, 2020. Accessed September 3, 2020.
121. Head, K., et al., Saline irrigation for allergic rhinitis.Cochrane Database Syst Rev, 2018. 6 : p. CD012597.
122. Mitsias, D.I., et al., Effect of nasal irrigation on allergic rhinitis control in children; complementarity between CARAT and MASK outcomes. Clin Transl Allergy, 2020. 10 : p. 9.
123. Kenney, P., et al., Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo-controlled crossover park study. J Allergy Clin Immunol, 2015. 136 (6): p. 1566-1572 e5.
124. Wu, A.W., et al., Alternative therapies for sinusitis and rhinitis: a systematic review utilizing a modified Delphi method. Int Forum Allergy Rhinol, 2020.
125. Fokkens, W., P. Hellings, and C. Segboer, Capsaicin for Rhinitis. Curr Allergy Asthma Rep, 2016. 16 (8): p. 60.
126. Halken, S., et al., EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol, 2017.28 (8): p. 728-745.
127. Mitsias, D.I., et al., Immunotherapy in allergic diseases - improved understanding and innovation for enhanced effectiveness. Curr Opin Immunol, 2020. 66 : p. 1-8.
128. Durham, S.R., et al., Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. J Allergy Clin Immunol, 2016.138 (4): p. 1081-1088 e4.
129. Jutel, M., et al., Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy, 2020.
130. Papadopoulos, N.G., et al., International consensus on (ICON) pediatric asthma. Allergy, 2012. 67 (8): p. 976-97.
131. Pitsios, C., et al., Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy, 2015. 70 (8): p. 897-909.
132. Pajno, G.B., et al., Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy, 2001.31 (9): p. 1392-7.
133. Lim, J.H., et al., Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One, 2017.12 (8): p. e0182295.
134. Di Bona, D., et al., Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy, 2017. 72 (5): p. 691-704.
135. Zielen, S., et al., Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy, 2018.73 (1): p. 165-177.
136. Jacobsen, L., et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy, 2007. 62 (8): p. 943-8.
137. Valovirta, E., et al., Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol, 2018.141 (2): p. 529-538 e13.
138. Prokopakis, E.P., L. Kalogjera, and A.D. Karatzanis,Pediatric Severe Chronic Upper Airway Disease (P-SCUAD). Curr Allergy Asthma Rep, 2015. 15 (12): p. 68.
139. Mathioudakis, A.G., et al., Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank. J Allergy Clin Immunol Pract, 2020. 8 (6): p. 1953-1960.e9.